Depression, generalized anxiety disorder, panic disorder
Conditions
Interventions
Depression:Paroxetine
Generalized Anxiety Disorder:Paroxetine
Panic Disorder:Paroxetine
Sponsors
Institute of Mental Health, the Sixth Hospital of Peking University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Study on the efficacy and adverse reactions of different CYP2D6 metabolites in the treatment of depression (1) The standard age of the patients was 18-65 years old; (2) Outpatients or inpatients; (3) Patients who met dsm-5 criteria for major depressive disorder; (4) Patients with HAMD-17 score >= 17; (5) Patients with manic symptom checklist-32 (hcl-32) = 14; (5) Patients with first onset (course of disease less than 3 months) or relapsed patients who have stopped antidepressant treatment for more than 3 months; (6) Patients who did not receive any systematic anti anxiety and depression treatment and did not use drugs that induce or inhibit metabolism of CYP2D6 within 2 weeks before enrollment; (7) Patients with junior high school education or above have no language communication barrier, can cooperate with assessment and treatment, and sign informed consent. 3. Study on the efficacy and adverse reactions of paroxetine in the treatment of panic disorder with different CYP2D6 metabolic types (1) Patients aged 18-65 years, of either gender, Han nationality; (2) Outpatients or inpatients; (3) Patients who met the dsm-5 criteria for panic disorder; (4) Patients with PDSS score >= 7; (5) Patients with first onset (course of disease less than 3 months) or relapsed patients who have stopped antidepressant treatment for more than 3 months; (6) Patients who did not receive any systematic anti anxiety and depression treatment and did not use drugs that induce or inhibit metabolism of CYP2D6 within 2 weeks before enrollment; (7) Patients with junior high school education or above have no language communication barrier, can cooperate with assessment and treatment, and sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Exclusion criteria of different CYP2D6 metabolites on the efficacy and adverse reactions of paroxetine in the treatment of depression: 1 (1) The patients who met the dsm-5 diagnosis before or at present: organic mental disorder, schizophrenia, schizophrenic affective disorder, bipolar disorder, mental retardation, dementia, other cognitive disorders, alcohol dependence and personality disorder, etc; (2) Patients with serious suicidal tendency are at risk of injury; (3) Patients with severe or unstable physical diseases; (4) Patients with narrow angle glaucoma had a history of epilepsy; (5) Known pregnancy and / or breastfeeding, or planned pregnancy; (6) Patients who participated in another clinical trial at the same time were unwilling or unable to complete the whole course of the trial; (7) Excluding physical diseases such as epilepsy, cardiovascular disease, pheochromocytoma, hyperthyroidism, or secondary depression and anxiety disorders such as spontaneous hypoglycemia. 2. Exclusion criteria for efficacy and adverse reactions of paroxetine in the treatment of generalized anxiety disorder with different CYP2D6 metabolic types (1) Patients who had been diagnosed with dsm-5 or below; (2) Patients with organic mental disorder, schizophrenia, schizophrenic affective disorder, bipolar disorder, mental retardation, dementia, other cognitive impairment, alcohol and drug dependence personality disorder; (3) Patients with serious suicidal tendency are at risk of injury; (4) Patients with severe or unstable physical diseases; (5) Patients with narrow angle glaucoma had a history of epilepsy; (6) Known pregnancy and / or breastfeeding, or planned pregnancy; (7) Patients who participated in another clinical trial at the same time were unwilling or unable to complete the whole course of the trial; (8) Depression and anxiety disorder secondary to somatic diseases such as epilepsy, cardiovascular disease, pheochromocytoma, hyperthyroidism or spontaneous hypoglycemia were excluded. 3. Exclusion criteria for efficacy and adverse reactions of paroxetine in the treatment of panic disorder with different CYP2D6 metabolites (1) The patients who met the dsm-5 diagnosis before or at present: organic mental disorder, schizophrenia, schizophrenic affective disorder, bipolar disorder, mental retardation, dementia, other cognitive disorders, alcohol dependence personality disorder, etc; (2) Patients with serious suicidal tendency are at risk of injury; (3) Patients with severe or unstable physical diseases; (4) Patients with narrow angle glaucoma had a history of epilepsy; (5) Known pregnancy and / or breastfeeding, or planned pregnancy; (6) Patients who participated in another clinical trial at the same time were unwilling or unable to complete the whole course of the trial; (7) Patients with physical diseases such as epilepsy, cardiovascular disease, pheochromocytoma, hyperthyroidism or spontaneous hypoglycemia were excluded. 4. Exit and termination criteria: Once the above exclusion criteria appear in the recruited patients, or the patients have intolerable adverse reactions, or the patients withdraw their informed consent to withdraw, the patients will immediately withdraw and terminate the study. Doctors should give termination evaluation and cooperate to develop necessary clinical alternative treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hamilton Depression Scale, HAMD;Hamilton Anxiety Scale, HAMA;Panic Disorder Severity Scale, PDSS; | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical global impression, CGI;Treatment Emergent Symptom Scale, TESS; | — |
Countries
China
Contacts
Public ContactYue Weihua
Institute of Mental Health, the Sixth Hospital of Peking University
Outcome results
None listed